Brean Capital Reiterates Buy and $7 Target on IntelliPharmaCeutics (IPCI)
Tweet Send to a Friend
Brean Capital maintained a Buy rating on IntelliPharmaCeutics International (NASDAQ: IPCI) with a price target of $7.00. Comments follow news ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
